Results 31 to 40 of about 1,814 (132)
Ophthalmology and Therapy, 2023 Introduction Intraocular inflammation (IOI)-related adverse events (AEs) that may result in severe vision loss have been associated with the anti-vascular endothelial growth factor brolucizumab.
Ryan Zubricky +8 more
doaj +1 more source
Nursing Open, Volume 13, Issue 9, September 2026.ABSTRACT Aim To compare patients' anticipated pain intensity and actual pain experienced during intravitreal injection. Design The study used a quantitative, cross‐sectional design. Methods A single‐centre study was conducted in a group of 115 patients. Data were collected using medical records and the Numerical Rating Scale (NRS).
Ewa Kobos, Katarzyna Leszczyńska
wiley +1 more source
Anti-VEGF Drugs Dynamics: Relevance for Clinical Practice
Pharmaceutics, 2022 Background: A drug and disease assessment model was used to evaluate the impact of different treatment regimens on intravitreal ranibizumab, bevacizumab, aflibercept, and brolucizumab concentrations and the proportion of free vascular endothelial growth ...
Daniele Veritti +3 more
doaj +1 more source
The impact of systemic long‐term medications for the development of age‐related macular degeneration
Acta Ophthalmologica, Volume 104, Issue 6, Page 674-681, September 2026.Abstract Purpose Age‐related macular degeneration (AMD) is a leading cause of central vision loss in the elderly; however, the systemic factors that modulate its incidence and progression remain unclear. We sought to determine whether long‐term use of systemic medications, including diabetes and antithrombotic medications, corticosteroids and ...
Hanna Heloterä +3 more
wiley +1 more source
International Journal of Retina and Vitreous, 2022 Background The current standard treatment for neovascular age-related macular degeneration (nAMD) involves intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents.
Sanjay Kumar Mishra +7 more
doaj +1 more source
iMeta, Volume 5, Issue 4, August 2026.Spatial multi‐omics of the mouse ocular globe after retinal ischemia‐reperfusion (RIR) injury identifies the ganglion cell layer (GCL) as an immunometabolic niche where Trem2+ microglia closely associate with stressed retinal ganglion cells (RGCs) through Trem2‐Apoe signaling.
Yunhong Shi +12 more
wiley +1 more source
The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta +2 more
wiley +1 more source
Indian Journal of Ophthalmology. Case Reports, 2023 Intraocular inflammation (IOI) has been reported after intravitreal brolucizumab injection. We report one such case of IOI successfully managed with intravitreal dexamethasone implant and hyperreflective foci (HRFs) as a novel OCT biomarker for IOI after
Vasumathy Vedantham +2 more
doaj +1 more source
The prechoroidal cleft in neovascular age‐related macular degeneration
Acta Ophthalmologica, Volume 104, Issue 4, Page 364-375, June 2026.Abstract The prechoroidal cleft is a lenticular, hypo‐reflective space on optical coherence tomography imaging, located between a band of fibrovascular material underneath the retinal pigment epithelium (RPE) and Bruch's membrane. It occurs in 8%–22% of neovascular age‐related macular degeneration (nAMD) eyes, most often with macular neovascularization
Niels J. Brouwer +3 more
wiley +1 more source
Journal of Ophthalmic & Vision Research, 2021 Age-related macular degeneration and its complication, subretinal neovascularization, are common causes of progressive, irreversible impairment of central vision. Anti-vascular endothelial growth factor (anti-VEGF) therapy has improved the visual outcome
Tahmineh Motevasseli +3 more
doaj +1 more source